Key result
Spectral analysis of Holter ECGs showed that peak fibrillatory frequency correlated with AF duration (R=0.53, p=0.002) and decreased from 6.9 Hz to 5.8 Hz after antiarrhythmic drug therapy (p<0.001).
Why the study?
Does spectral analysis of the fibrillatory baseline on Holter ECG correlate with AF duration and response to antiarrhythmic drugs in patients with paroxysmal and persistent AF?
Population
20 patients with atrial fibrillation
Comparison
Spectral analysis of Holter ECG recordings to… vs Baseline vs 3 to 5 days after initiation of…
Design
Cohort
Follow-up
3 to 5 days (for persistent AF group)
Authors
Loading...
May support noninvasive AF monitoring; hypothesis-generating for prospective outcome trials.
Observational (n=20)
Does spectral analysis of the fibrillatory baseline on Holter ECG correlate with AF duration and response to antiarrhythmic drugs in patients with paroxysmal and persistent AF?
Absolute Event Rate: 5.8% vs 6.9%
p-value: p=<0.001
Spectral analysis of the fibrillatory baseline on Holter ECG can predict the duration of paroxysmal AF episodes and monitor the response to antiarrhythmic medication in persistent AF.
Andreas Bollmann (1999) conducted an observational in Paroxysmal and persistent atrial fibrillation (n=20). Spectral analysis of Holter ECG / Antiarrhythmic drugs vs. Baseline was evaluated on Peak fibrillatory frequency (f) (p=<0.001). Spectral analysis of Holter ECGs showed that peak fibrillatory frequency correlated with AF duration (R=0.53, p=0.002) and decreased from 6.9 Hz to 5.8 Hz after antiarrhythmic drug therapy (p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: